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Future investigation is required to ﬁnd which modality (adjuvant 
chemotherapy vs. radiotherapy) needs to be given immediately after 
surgery for those with N2 disease and negative margin. 
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Assessment of mediastinal disease: invasive approach vs PET: the 
case for invasive techniques
Jablons, David M. Kim, Jae 
UCSF, San Francisco, CA, USA
Accurate staging of the mediastinum in non-small cell lung cancer is 
essential to appropriately determine if patients should be candidates for 
surgical resection, neo-adjuvant therapy, or for deﬁnitive chemoradia-
tion. It has been shown that patients with persistent, bulky N2 disease 
following induction therapy have poor survival if they go on to surgery. 
Thus, re-staging patients after induction therapy is becoming even more 
important; however, the ideal method of staging the mediastinum is 
still under debate. With the continued development of new minimally 
invasive techniques, such as endobronchial ultrasound (EBUS) guided 
transbronchial needle biopsy and VATS staging, the question is sure to 
evolve.
Mediastinoscopy.
Cervical mediastinoscopy is the current gold standard for mediastinal 
staging. Pooling data from several studies, Toloza et al, found that 
cervical mediastinoscopy had a sensitivity of 81% and speciﬁcity 
approaching 100%; for a positive predictive value of 1.0 and nega-
tive predictive value of 0.91.1 In contrast, PET had an overall positive 
predictive value of 0.79 and negative predictive value of 0.93.2 The 
main risk with PET is that some patients with pathologically negative 
mediastinal disease may continue to have FDG-avid lymph nodes. 
Thus, some patients with potentially curable disease will be denied 
surgical intervention. Standard cervical mediastinoscopy is not able to 
sample aortopulmonary window, paraesophageal, and pulmonary liga-
ment nodes. Other drawbacks include the need for general anesthesia, 
the risk of bleeding, and risk of recurrent laryngeal nerve injury. 
Chamberlain Procedure and Video-Assisted Thoracic Surgery 
(VATS)
A left anterior parasternal mediastinotomy, or Chamberlain procedure, 
provides access to the subaortic space, however, generally requires 
division of costal cartilage. The sensitivity and speciﬁcity are 74% 
and 100% respectively. VATS also allows sampling of the AP window 
nodes. If performed at the time of deﬁnitive resection, an initial VATS 
sampling of ipsilateral mediastinal lymph nodes with frozen section 
may prevent the surgeon from going on to perform an unnecessary 
resection. There have been relatively little data comparing the accuracy 
of VATS staging to either PET or conventional mediastinoscopy. Like 
mediastinoscopy, these procedures require general anesthesia and carry 
a risk of bleeding.
Endoscopic and endobronchial ultrasound.
Endoscopic ultrasound guided ﬁne-needle aspiration (EUS-FNA) 
allows access to left sided paratracheal nodes, as well as para-aortic, 
subcarinal, para-esophageal, and sometimes inferior pulmonary liga-
ment nodes. For these lymph nodes, EUS-FNA has been shown to have 
comparable sensitivity and speciﬁcity to CT and PET. The diagnostic 
accuracy is further increased if there is lymph node enlargement. En-
dobronchial ultrasound (EBUS) is a relatively newer method of staging 
that uses an ultrasound transducer mounted on a videobronchoscope to 
guide FNA. It can be used to biopsy paratracheal, subcarinal, and peri-
bronchial nodes; in experienced hands, even some AP window nodes 
can be biopsied safely. In the few published case series, the sensitivity 
and speciﬁcity are roughly 85% and 100% respectively. Both EUS and 
EBUS can be done relatively quickly, without general anesthesia, and 
with a minimal complication rate. Combined, EUS and EBUS have the 
potential to accurately stage the entire mediastinum with low morbidity. 
Overview
The role for invasive staging of the mediastinum continues to evolve 
as new technologies emerge. Randomized trials comparing the newer 
methods with established methods are necessary. Although it is yet 
unclear which method or methods will become the new standard, all 
these invasive approaches have one distinct advantage over non-in-
vasive methods like CT or PET - access to tissue. For patients with 
mediastinal disease, these procedures can be used to make a deﬁni-
tive tissue diagnose at the same time as staging, which is required for 
initiation of induction therapy. In addition, as molecular proﬁling of 
tumors becomes more important, being able to analyze the biology of 
the tumor (both pre- and post-induction) may add another dimension to 
individually tailored treatment regimens. 
1. Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell 
lung cancer: a review of the current evidence. Chest 2003;123:157S-166S.
2. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung 
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Hurdles in the Development of a New Drug
Vokes, Everett E. 
The University of Chicago, Chicago, IL, USA
Investigations of novel agents remain a cornerstone of clinical research 
in Oncology. Guidelines for investigations of novel agents have existed 
for many years. They include sequential investigations of a novel agent 
in the phase I, II and III setting. It is clear that the classical phase II 
study design is not particularly well suited to investigations of targeted 
agents since it may not result in measurable objective responses. Al-
ternative trial designs have been investigated over recent years. These 
include a randomized phase II trials as well as randomized discontinu-
ation trials and dose range trials. Examples of such studies and their 
impact on recent drug development will be presented. 
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Career choices: options in academia, private practice, industries 
and government
Le Chevalier, Thierry 
GSK & Institut Gustave Roussy, Villejuif, France, Greenford, UK
A Medical Doctor studies for longer than most any other profession. 
The reason for this is that there is a considerable amount of knowledge 
required in order to be able to provide a correct diagnosis and cure 
to patients in his area of speciality. If diagnostic part of his activity is 
directly related to clinical practice (academic and/or private), the imple-
mentation of this activity requires a medically driven/controlled admin-
istrative organization. The dramatic improvement, technicality, cost and 
speciﬁcity of diagnostic procedures make the role of a single physician 
less and less predominant and the need for regulation more and more 
important. A medical input is necessary to determine which procedures 
are the most appropriate and should be available for all patients.
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Treatments have also considerably evolved in the last decades. The 
choices of treatment for a single patient are more often limited by strict 
guidelines which relegate the physician to the role of executor. He must 
know everything and he has only one (or few) options for each single 
patient. 
The way to improve treatments is through clinical research and the role 
of the physician may be either in the R&D process (i.e. in industry) or 
close to the patient (mostly in academic institutions).
Each of these activities (teaching, providing care, organizing, research-
ing) require experienced doctors. No job fully covers these activities 
simultaneously.
Patient cure should be the ﬁrst, and often the only, activity of most 
Medical Oncologists within their working-life cycle. Nevertheless, one 
can be attracted by the desire of an academic activity (power), private 
practice (monetary), government (honor) or decide to join industry 
(clinical research at its source) with a mixture of these recognitions.
Below are summarized some of the aspects of the four major areas 
where Medical Oncologists can utilize their expertise and realize their 
aspiration.
Academy
Pro: clinical research, prestige, recognition, team, leadership, advisor 
ship, no professional cell phone, safety
Limits: Money, lack of private relations, diluted responsibility, uncer-
tainty
Private Practice
Pro: individual relationship with patients, less constraining rules, 
responsibility, freedom, ﬁnancial issues 
Limits: no clinical research, no KOL recognition, permanently on call
Industries
Pro: clinical research, team-working, recognition, facilities, resourcing, 
impact
Limits: lack of patients, lack of freedom, uncertainty
Government
Pro: ethical, social, impact on public health, inﬂuencing policy makers 
and payers
Limits: no patients, no clinical research, budget constraints
The chance we have is that all these activities have exciting aspects! 
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Pharmacogenomic applications in the management of Non-Small 
Cell Lung Cancer (NSCLC): from clinical trials to clinical practice
Simon, George 
H. Lee Mofﬁtt Cancer Center, Tampa, FL, USA
Introduction: 
Wide applicability of personalized therapy remains a challenge, a 
challenge that must be surpassed to improve standard of care for the 
vast majority of patients who are treated in the community. Techniques 
utilized in personalizing care must therefore be 1) simple to apply 2) 
easily standardized and reproducible. However, before an investiga-
tional approach is deemed suitable for wider application it must ﬁrst be 
rigorously tested in a controlled clinical research environment. 
We applied pharmacogenomic techniques to assess its ability to 
prognosticate as well as to predict response to speciﬁc chemotherapy 
drugs, commonly used in the treatment of NSCLC. In the interest of 
simplicity we utilized the candidate gene approach (versus the gene 
array approach) where we utilized two genes (Excision Repair Cross-
Complementing gene 1 (ERCC1) and Ribonucleotide Reductase M 
Subunit-1 (RRM1)). 
We ﬁrst validated the utility of both these genes in the controlled set-
ting of a clinical trial in a tertiary referral cancer center utilizing the 
real-time quantitative reverse transcriptase polymerase chain reaction 
(RT-PCR) technique to measure the expression of the aforementioned 
genes. The use of RT-PCR in fresh tissue, to measure gene expression, 
is stringent but cumbersome. Once these ‘proof of principle’ studies 
were successfully completed and appeared to show patient beneﬁt, 
additional testing in a phase III or multi-center setting was undertaken 
and is currently under way. The technique being utilized to measure the 
activity of ERCC1 and RRM1 genes, for these ‘validation’ studies, is 
the more widely applicable techniques of immunohistochemistry (IHC) 
or automated quantitative protein analyses (AQUA). 
The results of some of ‘proof of principle’ studies and the current status 
of the validation studies are detailed below. 
ERCC1 as a Predictor Of Response To Chemotherapy in Patients 
With Advanced NSCLC
The platinum compounds, speciﬁcally cisplatin and carboplatin, are 
heavy metal complexes that form adducts and covalent cross-links 
between DNA double strands and thus effectively blocks DNA replica-
tion and transcription. ERCC1 gene encodes a protein that is part of a 
complex of molecules in the nuclear excision repair (NER) pathway 
that repairs these DNA strand breaks. In gastric cancer(1), ovarian(2), 
oesophageal(3), colorectal(4), non-small cell lung cancer(5) and more 
recently in breast cancer(6) increased expression of ERCC1 was found 
to predict for decreased response and survival when cisplatin-based 
treatments are utilized. 
Molecular Analyses Directed Individualized Therapy Trials In 
Patients With Advanced NSCLC 
We conducted to a prospective phase II clinical trial to test the feasibil-
ity and efﬁcacy of molecular analysis-directed individualized therapy 
(MADe IT) in patients with advanced NSCLC (7). We hypothesized 
that selection of dual agent chemotherapy based on tumoral ERCC1 
and RRM1 expression would be feasible and beneﬁcial for patients 
with advanced NSCLC. RRM1 is the regulatory subunit of ribonucleo-
tide reductase, an essential metabolic enzyme required for cellular 
proliferation, that catalyzes the reduction of ribonucleoside diphos-
phates to the corresponding deoxyribonucleotides (8) (9). RRM1 is the 
molecular target of gemcitabine (2’-2’diﬂuorodeoxycytidine) which 
is an antimetabolite with activity in several malignancies, and is an 
efﬁcacious agent in NSCLC (10) (11). Patients were required to have 
a dedicated tumor biopsy for determination of RRM1 and ERCC1 
gene expression by RT-PCR. Dual agent chemotherapy consisting 
of carboplatin, gemcitabine, docetaxel, and vinorelbine was selected 
based on gene expression. Disease response and patient survival were 
monitored. Collection of tumor specimens with gene expression analy-
sis was feasible in 55 of the 60 patient undergoing a dedicated tumor 
biopsy. RRM1 expression ranged from 0-1,637, ERCC1 expression 
ranged from 1-8,103, and their expression was correlated (Spearman’s 
rho=0.46, p<0.01). (RRM1 and ERCC1 gene expression was denoted 
as a ratio of the house keeping gene 18SrRNA and hence unit-less.) 
Disease response was 44%. Overall and progression-free survival 
and were 59% and 14% at 12 months with medians of 13.3 and 6.6 
months respectively. We therefore concluded that therapeutic decision 
making based on RRM1 and ERCC1 gene expression for patients with 
